Company Overview
Snapshot
Founded in April 2021 by Shmuel Mandel, PsygaBio operates with 1–10 employees. The company has secured funding across one round from NFX Capital. PsygaBio is focused on drug discovery, leveraging natural compounds for therapeutic development.
Business overview
PsygaBio is a drug discovery company specializing in developing therapeutics derived from natural compounds. Utilizing Cannasoul's proprietary analytical platform, PsygaBio employs a data-driven approach, expertise, and a clinical trial framework to identify and develop active compounds. This process spans from mushroom cultivation and extraction to clinically approved formulations. In partnership with Cannasoul Analytics, PsygaBio aims to explore the diversity of psychedelic mushrooms to identify active compounds and formulations for therapeutic benefits, operating within the Health Tech & Life Sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- What is PsygaBio's primary focus?
- PsygaBio is a drug discovery company focused on developing therapeutics derived from natural compounds, utilizing a data-driven approach for active compound identification and formulation.
- When was PsygaBio founded?
- PsygaBio was founded in April 2021.
- Who is a co-founder of PsygaBio?
- Shmuel Mandel is a co-founder and CEO of PsygaBio.
- What is PsygaBio's relationship with Cannasoul Analytics?
- PsygaBio is a subsidiary of Cannasoul Analytics and partners with them to exploit the diversity found in psychedelic mushrooms to identify active compounds and formulations for therapeutic benefits.
- What is PsygaBio's product development stage?
- PsygaBio's products are currently in the R&D stage, as of their Seed funding round in September 2021.